In these contexts, we elucidated a new mechanism of GC chemoresistance and found that a high level of ZFP64 plays a critical role in GC progression and chemotherapy resistance by regulating the stem cell-like phenotype and suppressing pathogenic immune activation, suggesting that the disruption of ZFP64-related signaling may inhibit the development of GC and reverse nab-paclitaxel resistance in GC (Fig. 9). This evidence concerns the gene ZFP64 and gastric cancer.